Pivotal Practice Views with the Oncology Brothers

Rahul Gosain, MD, MBA; Rohit Gosain, MD; and Anwaar Saeed, MD, evaluate the RATIONALE-305 and RATIONALE-306 trials, investigating tislelizumab and examining the trials’ key end points, including overall survival, progression-free survival, and safety outcomes.

Panelists discuss the FDA approval of subcutaneous nivolumab based on the CheckMate-67T trial findings, highlighting its potential to improve patient convenience and treatment adherence while maintaining efficacy in the treatment of melanoma.

Along with the Oncology Brothers, Paolo Tarantino, MD, discuss the phase 3 EMERALD study of elacestrant versus standard-of-care endocrine therapy for estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC). Their conversation focuses on the implications of recently published data demonstrating that elacestrant provides a PFS benefit across clinically meaningful subgroups of patients with ESR1-mutated (ESR1m), ER+, HER2- MBC, including those with endocrine-sensitive disease.

Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309. https://doi.org/10.1158/1078-0432.CCR-24-1073.

Panelists discuss how the FDA approval of durvalumab, based on the AEGEAN trial, represents a significant advancement in treatment options, potentially improving patient outcomes in clinical practice.

Panelists discuss various stages of graft-vs-host disease (GVHD) and chronic GVHD (cGVHD), and the study of axatilimab as a treatment within the AGAVE-201 study.

Arvind Dasari, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, of Oncology Brothers, to discuss the FRESCO-2 data and its impact on the colorectal cancer landscape.

Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the EV-302 study and the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.

Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the FDA approval of zanubrutinib and where it fits in clinical practice, highlighting data from the ALPINE and SEQUOIA studies.

Hope Rugo, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss data from CAPItello-291 on capivasertib and how it has changed the treatment landscape in HR+ breast cancer.

Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by expert Jonathan Friedberg, MD, MMSc, in their review of respective data from POLARIX in DLBCL and SWOG S1826 in Hodgkin’s Lymphoma.

The Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Jonathan E. Rosenberg, MD, to discuss recent data from a phase 2 study investigating enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic bladder cancer.

Expert oncologist Virginia Kaklamani, MD, DSc, joins the Oncology Brothers to review data from the EMERALD trial and discuss use of the oral SERD, elacestrant, in patients with ER+, HER2- advanced breast cancer.